Difference between revisions of "Part:BBa K4165150"
 
(One intermediate revision by the same user not shown)
Line 15: Line 15:
  
 
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
 
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
−
APT were modeled by AlphaFold2, Apptest, ITASSER and RosettaFold. best model is obtained from AlphaFold2 and the model is shown below
+
APT was modeled by AlphaFold2, Apptest, iTASSER and RosettaFold. The best model is obtained from AlphaFold2 ranking 4 out of 6
−
 
+
  
  
 
<html>
 
<html>
−
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/apt.png" style="margin-left:300px;" alt="" width="500" /></p>
+
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/apt.png" style="margin-left:300px;" alt="" width="300" /></p>
 
</html>
 
</html>
  

Latest revision as of 14:27, 11 October 2022


APT Peptide

A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils.


Usage and Biology

This part is derived from D-enantiomeric peptide acquired by mirror image phage display, its amino acid sequence is (APTLLRLHSLGA), that can bind to PHF seed (VQIVYK), its half maximal concentration for tau fibril formation inhibition is 139.6 μM. In addition, it has low cell penetration ability.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry Lab

Modeling

APT was modeled by AlphaFold2, Apptest, iTASSER and RosettaFold. The best model is obtained from AlphaFold2 ranking 4 out of 6 


                            Figure 1.: Predicted 3D structure of Synthetic peptide APT.

Table 1: Quality assessment parameters of TLKIVW model.


References

1. Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432.